Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TPH1 | P17752 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8532710 | 0.87 | SLC6A4 (0.54) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL15139563 | 0.84 | LDHA (0.65) | LDHASLC6A4MMP3PPARGPPARA | |
| SCHEMBL663059 | 0.84 | LDHA (0.73) | LDHASLC6A4MMP3PPARGPPARA | |
| SCHEMBL8283100 | 0.84 | LDHA (0.73) | LDHASLC6A4MMP3PPARGPPARA | |
| SCHEMBL18929189 | 0.83 | ANPEP (0.43) | LDHAENPEP | |
| SCHEMBL8283122 | 0.83 | ENPEP (0.49) | PPARGPPARAENPEP | |
| SCHEMBL12879843 | 0.83 | ENPEP (0.49) | ENPEP | |
| SCHEMBL15134788 | 0.83 | ENPEP (0.49) | ENPEP | |
| SCHEMBL12873867 | 0.83 | ENPEP (0.49) | ENPEP | |
| SCHEMBL15147781 | 0.83 | ENPEP (0.49) | PPARGPPARAENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980833-B2 | Tubulysine derivatives | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| EP-2532673-A2 | Tubulysine derivatives | R & D Biopharmaceuticals Gmbh (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2008138561-A1 | TUBULYSINE DERIVATIVES | R & D BIOPHARMACEUTICALS GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | GLS, TPX2, HKDC1 | LDHA 1893/4885SLC6A4 1280/4885MMP3 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.